索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|


点击复制

肌少症诊治研究进展(PDF)

《国际骨科学杂志》[ISSN:1673-7083/CN:31-1952/R]

期数:
2022年06期
页码:
357-361
栏目:
综述
出版日期:
2022-12-01

文章信息/Info

Title:
-
文章编号:
10.3969/j.issn.1673-7083.2022.06.008
作者:
尤聪瑶;杨铁毅;
200444, 上海大学医学院(尤聪瑶);200135, 上海市 浦东新区公利医院骨科、上海大学医工交叉研究院运动健康研究室(杨铁 毅)
Author(s):
-
关键词:
肌少症诊断病理生理学治疗
Keywords:
-
分类号:
-
DOI:
-
文献标识码:
-
摘要:
肌少症是一种进行性和广泛性骨骼肌疾病,主要指肌肉质量和肌肉功能的加速丧失,常出现跌倒、骨折、 伤残等状况,严重增加了老年人的生活负担。肌少症主要发病机制有衰老、运动减少、激素失调、线粒体功能障碍及 炎症反应等,但其具体的发病机制尚未统一。肌少症的一般诊断流程分为4 步: 发现- 评估- 确诊- 严重程度分级,不 同的诊断流程采用不同的诊断方法。这些方法各有利弊且存在一定的差异性,使得文献报道的流行病学存在较大差异。 目前,对肌少症发病机制尚未有统一的观点,其治疗方法主要有运动治疗、营养治疗、药物治疗和康复治疗等。该文 就肌少症的定义、流行病学、发病机制、诊断标准、治疗等方面的研究进展进行综述。
Abstract:
-

参考文献/References

[1] Cruz-Jentoft AJ, Sayer AA. Sarcopenia[J]. Lancet, 2019, 393(10191): 2636-2646.
[2] Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis[J]. Age Ageing, 2019, 48(1): 16-31.
[3] Barazzoni R, Bischoff SC, Boirie Y, et al. Sarcopenic obesity: time to meet the challenge[J]. Clin Nutr, 2018, 37(6 Pt A): 1787-1793.
[4] 中华医学会骨质疏松和骨矿盐疾病分会. 肌少症共识[J]. 中华骨 质疏松和骨矿盐疾病杂志, 2016, 9(03): 215-227.
[5] Mayhew AJ, Amog K, Phillips S, et al. The prevalence of sarcopenia in community-dwelling older adults, an exploration of differences between studies and within definitions: a systematic review and metaanalyses[ J]. Age Ageing, 2019, 48(1): 48-56.
[6] Kitamura A, Seino S, Abe T, et al. Sarcopenia: prevalence, associated factors, and the risk of mortality and disability in Japanese older adults[J]. J Cachexia Sarcopenia Muscle, 2021, 12(1): 30-38.
[7] Pang BWJ, Wee SL, Lau LK, et al. Prevalence and associated factors of sarcopenia in Singaporean adults-The Yishun Study[J]. J Am Med Dir Assoc, 2021, 22(4): 885.e1-885.e10.
[8] Chen Z, Li WY, Ho M, et al. The Prevalence of sarcopenia in Chinese older adults: meta-analysis and meta-regression[J]. Nutrients, 2021, 13(5): 1441.
[9] Wiedmer P, Jung T, Castro JP, et al. Sarcopenia - Molecular mechanisms and open questions[J]. Ageing Res Rev, 2021, 65: 101200.
[10] Goljanek-Whysall K, Iwanejko LA, Vasilaki A, et al. Ageing in relation to skeletal muscle dysfunction: redox homoeostasis to regulation of gene expression[J]. Mamm Genome, 2016, 27(7-8): 341-357.
[11] Gensous N, Bacalini MG, Franceschi C, et al. Age-related DNA methylation changes: potential impact on skeletal muscle aging in humans[J]. Front Physiol, 2019, 10: 996.
[12] Li L, Xiong WC, Mei L. Neuromuscular junction formation, aging, and disorders[J]. Annu Rev Physiol, 2018, 80: 159-188.
[13] Wohlwend M, Laurila PP, Williams K, et al. The exercise-induced long noncoding RNA CYTOR promotes fast-twitch myogenesis in aging[J]. Sci Transl Med, 2021, 13(623): eabc7367.
[14] Bian A, Ma Y, Zhou X, et al. Association between sarcopenia and levels of growth hormone and insulin-like growth factor-1 in the elderly[J]. BMC Musculoskelet Disord, 2020, 21(1): 214.
[15] Halmos T, Suba I. The physiological role of growth hormone and insulin-like growth factors[J]. Orv Hetil, 2019, 160(45): 1774-1783.
[16] Morley JE. Hormones and sarcopenia[J]. Curr Pharm Des, 2017, 23(30): 4484-4492.
[17] Argilés JM. The 2015 ESPEN Sir David Cuthbertson lecture: Inflammation as the driving force of muscle wasting in cancer[J]. Clin Nutr, 2017, 36(3): 798-803.
[18] Argilés JM, Busquets S, Toledo M, et al. The role of cytokines in cancer cachexia[J]. Curr Opin Support Palliat Care, 2009, 3(4): 263- 268.
[19] 于宝海, 吴文娟. 2018 欧洲肌少症共识解读[J]. 河北医科大学学 报, 2019, 40(4): 373-379.
[20] 姜珊, 康琳, 刘晓红. 2019 亚洲肌少症诊断及治疗共识解读[J]. 中华老年医学杂志, 2020, 39(4): 373-376.
[21] Mazocco L, Chagas P, Barbosa-Silva TG, et al. Accuracy of SARC-F and SARC-CalF for sarcopenia screening in older women from southern Brazil[J]. Nutrition, 2020, 79-80: 110955.
[22] Fu X, Tian Z, Thapa S, et al. Comparing SARC-F with SARC-CalF for screening sarcopenia in advanced cancer patients[J]. Clin Nutr, 2020, 39(11): 3337-3345.
[23] Auyeung TW, Arai H, Chen LK, et al. Letter to the editor: Normative data of handgrip strength in 26344 older adults: a pooled dataset from eight cohorts in Asia[J]. J Nutr Health Aging, 2020, 24(1): 125-126.
[24] Albano D, Messina C, Vitale J, et al. Imaging of sarcopenia: old evidence and new insights[J]. Eur Radiol, 2020, 30(4): 2199-2208.
[25] Bosy-Westphal A, Schautz B, Later W, et al. What makes a BIA equation unique? Validity of eight-electrode multifrequency BIA to estimate body composition in a healthy adult population[J]. Eur J Clin Nutr, 2013, 67(Suppl 1): S14-S21.
[26] Cheng KYK, Chow SKH, Hung VWY, et al. Diagnosis of sarcopenia by evaluating skeletal muscle mass by adjusted bioimpedance analysis validated with dual-energy X-ray absorptiometry[J]. J Cachexia Sarcopenia Muscle, 2021, 12(6): 2163-2173.
[27] Tagliafico AS, Bignotti B, Torri L, et al. Sarcopenia: how to measure, when and why[J]. Radiol Med, 2022, 127(3): 228-237.
[28] Mitsiopoulos N, Baumgartner RN, Heymsfield SB, et al. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography[J]. J Appl Physiol (1985), 1998, 85(1): 115-122.
[29] Beretta-Piccoli M, Cescon C, Barbero M, et al. Reliability of surface electromyography in estimating muscle fiber conduction velocity: a systematic review[J]. J Electromyogr Kinesiol, 2019, 48: 53-68.
[30] Chowdhury RH, Reaz MBI, Ali MABM, et al. Surface electromyography signal processing and classification techniques[J]. Sensors (Basel), 2013, 13(9): 12431-12466.
[31] Narici M, McPhee J, Conte M, et al. Age-related alterations in muscle architecture are a signature of sarcopenia: the ultrasound sarcopenia index[J]. J Cachexia Sarcopenia Muscle, 2021, 12(4): 973-982.
[32] Schaap LA. D3-Creatine dilution to assess muscle mass[J]. J Gerontol A Biol Sci Med Sci, 2019, 74(6): 842-843.
[33] Zhu K, Wactawski-Wende J, Ochs-Balcom HM, et al. The association of muscle mass measured by D3-Creatine dilution method with dual-energy X-Ray absorptiometry and physical function in postmenopausal women[J]. J Gerontol A Biol Sci Med Sci, 2021, 76(9): 1591-1599.
[34] Kakehi S, Wakabayashi H, Inuma H, et al. Rehabilitation nutrition and exercise therapy for sarcopenia[J]. World J Mens Health, 2022, 40(1): 1-10.
[35] 邓玉洁, 李维辛. 运动改善肌少症的免疫机制研究进展[J]. 基础 医学与临床, 2021, 41(6): 909-913.
[36] 周晓宁, 许金海, 王国栋, 等. 肌少症治疗[J]. 中华骨质疏松和骨 矿盐疾病杂志, 2020, 13(3): 272-279.
[37] 杨则宜, 焦颖, 魏冰, 等. 老年肌肉减少症防治中的营养干预[J]. 中国食品学报, 2019, 19(9): 1-12.
[38] Rooks D, Roubenoff R. Development of pharmacotherapies for the treatment of sarcopenia[J]. J Frailty Aging, 2019, 8(3): 120-130.
[39] Hardee JP, Lynch GS. Current pharmacotherapies for sarcopenia[J]. Expert Opin Pharmacother, 2019, 20(13): 1645-1657.
[40] Devrimsel G, Metin Y, Serdaroglu Beyazal M. Short-term effects of neuromuscular electrical stimulation and ultrasound therapies on muscle architecture and functional capacity in knee osteoarthritis: a randomized study[J]. Clin Rehabil, 2019, 33(3): 418-427.
[41] 陈蓉, 曾庆, 巩泽, 等. 不同模式下血流限制治疗老年性肌肉减少 症的效果与安全因素[J]. 中国组织工程研究, 2021, 25(32): 5215- 5221.

备注/Memo

备注/Memo:
通信作者:杨铁毅 E-Mail: 1873310603@qq.com
更新日期/Last Update: 2022-12-01